EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinical advances in later-line therapy for metastatic or refractory colorectal cancer

Li Ma, Xia Liu, Ying Zhang, Yong Luo

World Journal of Gastroenterology · 2027-01-14 · 33 (2)

DOI: 10.3748/wjg.123996 ↗
AbstractBibliografische Angaben

Abstract

Metastatic colorectal cancer still ranks among the leading causes of cancer-related death globally owing to its poor treatment response. For patients with progression after first-line therapy, especially those with microsatellite-stable/proficient mismatch repair tumors or tumors harboring BRAF V600E or KRAS G12C mutations, high-quality evidence for optimal therapies remains scarce. This review summarizes clinical studies from the past 5 years on second-line and subsequent therapies for metastatic colorectal cancer, covering optimized combinations of chemotherapy, targeted therapy, immunotherapy, and radiotherapy, along with evaluations of novel agents. A review of these clinical advances reveals that chemotherapy regimens based on raltitrexed or trifluridine/tipiracil hydrochloride mixture (TAS-102) have demonstrated favorable efficacy in patients with fluoropyrimidine resistance. Antiangiogenic agents, epidermal growth factor receptor/human epidermal growth factor receptor 2/mesenchymal-epithelial transition factor blockade, BRAF inhibitors, and KRAS G12C inhibitors prolong survival. Immunotherapy yields durable responses in microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer, especially with dual immune checkpoint inhibition. Combinations of drugs with different mechanisms of action may treat refractory microsatellite-stable/proficient mismatch repair disease. Novel antibody-drug conjugates and other antitumor agents offer new options for previously treated patients. Limited high-quality evidence hinders optimal regimen selection. Future work should focus on improving individualized therapy and multidisciplinary management.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →